D.E. Shaw & Co
ACRS icon

D.E. Shaw & Co’s Aclaris Therapeutics ACRS Stock Holding History

D.E. Shaw & Co’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.19M Sell
414,499
-486,305
-54% -$2.17M ﹤0.01% 3123
2026
Q1 		$3.38M Sell
900,804
-1,195,847
-57% -$4.03M ﹤0.01% 2483
2025
Q4 		$6.31M Sell
2,096,651
-276,575
-12% -$699K ﹤0.01% 2118
2025
Q3 		$4.51M Sell
2,373,226
-427,056
-15% -$745K ﹤0.01% 2316
2025
Q2 		$3.98M Sell
2,800,282
-144,230
-5% -$195K ﹤0.01% 2201
2025
Q1 		$4.51M Sell
2,944,512
-349,113
-11% -$745K ﹤0.01% 1974
2024
Q4 		$8.17M Sell
3,293,625
-78,224
-2% -$195K 0.01% 1626
2024
Q3 		$3.88M Buy
3,371,849
+51,643
+2% +$63.3K ﹤0.01% 2152
2024
Q2 		$3.65M Buy
3,320,206
+37,224
+1% +$43.7K ﹤0.01% 2100
2024
Q1 		$4.07M Buy
3,282,982
+1,343,972
+69% +$1.6M ﹤0.01% 2045
2023
Q4 		$2.04M Buy
1,939,010
+1,873,000
+2,837% +$5.71M ﹤0.01% 2649
2023
Q3 		$452K Buy
66,010
+37,087
+128% +$317K ﹤0.01% 3468
2023
Q2 		$300K Buy
+28,923
New +$262K ﹤0.01% 3597
2022
Q1 		– Sell
-22,864
Closed -$332K – 5479
2021
Q4 		$332K Sell
22,864
-40,758
-64% -$617K ﹤0.01% 4633
2021
Q3 		$1.15M Sell
63,622
-205,633
-76% -$3.3M ﹤0.01% 3497
2021
Q2 		$4.73M Buy
+269,255
New +$6.12M ﹤0.01% 2097
2020
Q1 		– Sell
-69,769
Closed -$132K – 3879
2019
Q4 		$132K Sell
69,769
-631,696
-90% -$1.05M ﹤0.01% 3855
2019
Q3 		$758K Buy
701,465
+32,206
+5% +$45.7K ﹤0.01% 2984
2019
Q2 		$1.47M Sell
669,259
-1,183,610
-64% -$6.45M ﹤0.01% 2452
2019
Q1 		$11.1M Sell
1,852,869
-425,495
-19% -$2.82M 0.01% 1042
2018
Q4 		$16.8M Buy
2,278,364
+950,781
+72% +$9.8M 0.02% 785
2018
Q3 		$19.3M Buy
1,327,583
+58,668
+5% +$1.01M 0.02% 789
2018
Q2 		$25.3M Buy
1,268,915
+30,629
+2% +$566K 0.03% 606
2018
Q1 		$21.7M Buy
1,238,286
+215,158
+21% +$4.56M 0.03% 624
2017
Q4 		$25.2M Buy
1,023,128
+1,010,970
+8,315% +$24.6M 0.03% 575
2017
Q3 		$314K Buy
+12,158
New +$326K ﹤0.01% 3122

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

D.E. Shaw & Co's ACRS Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Aclaris Therapeutics (ACRS) stake by 54% in Q2 2026, selling an estimated $2.17M and leaving 414,499 shares worth $2.19M. The position accounts for ﹤0.01% of the portfolio, ranked #3123.

D.E. Shaw & Co first reported a position in ACRS in Q3 2017 and has held it in 26 quarters since. The position peaked at $25.3M in Q2 2018. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • D.E. Shaw & Co held 414,499 shares of Aclaris Therapeutics worth $2.19M as of Q2 2026.
  • D.E. Shaw & Co sold 486,305 Aclaris Therapeutics shares in Q2 2026, an estimated $2.17M.
  • Aclaris Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3123 holding.
  • D.E. Shaw & Co first reported a position in Aclaris Therapeutics in Q3 2017 and has held it in 26 quarters since.
  • D.E. Shaw & Co's Aclaris Therapeutics position peaked at $25.3M in Q2 2018.
  • 149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.